NewAmsterdam Pharma Company NAMS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Based on the most recent quarter.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's debt-to-equity?
- NewAmsterdam Pharma Company (NAMS) reported debt-to-equity of 0× in Q1 2026.
- How has NewAmsterdam Pharma Company's debt-to-equity changed year-over-year?
- NewAmsterdam Pharma Company's debt-to-equity decreased by 100.0% year-over-year, from 0× to 0×.
- What is the long-term trend for NewAmsterdam Pharma Company's debt-to-equity?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's debt-to-equity has grown at a 0.0% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.